Gastroösophageale Refluxkrankheit – Ergebnisse einer - DGVS

Leitlinie 190
55 Eckhardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in
patients with Barrett’s esophagus: a prospective controlled investigation.
Am J Med 2001; 111: 33– 37
56 O’Connor J, Falk G, Richter J. The incidence of adenocarcinoma and
dysplasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s
Esophagus Registry. Am J Gastroenterol 1999; 94: 2037–2042
57 Shaheen N, Crosby M, Bozymski E et al. Is there a publication bias in
the reporting of cancer risk in Barrett’s esophagus? Gastroenterology
2000; 119: 333 – 338
58 Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma
arising from Barrett’s metaplasia has regional variations in the west.
Gastroenterology 2002; 122: 588–590
59 Provenzale D, Schmitt C, Wong J. Barrett’s esophagus: A new look at
surveillance based on emerging estimates of cancer risk. Am J Gastroenterol
1999; 94: 2043 –2053
60 Sampliner RE. Practice Parameters Committee of the American College
of Gastroenterology. Updated guidelines for the diagnosis, surveillance,
and therapy of Barrett’s esophagus. Am J Gastroenterol
2002; 97: 1888 – 1895
61 Weston A, Krmpotich P, Cherian R et al. Prospective long-term endoscopic
and histological follow-up of short segment Barrett’s esophagus:
Comparison with traditional long segment Barrett’s esophagus.
Am J Gastroenterol 1997; 92: 407–413
62 Wright TA. High-grade dysplasia in Barrett’s oesophagus. Br J Surg
1997; 84: 760 – 766
63 Weston AP, Sharma P, Topalovski M et al. Long-term follow-up of Barrett’s
high-grade dysplasia. Am J Gastroenterol 2000; 95: 1888 – 1893
64 Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management
of Barrett’s esophagus with high-grade dysplasia. Gastroenterology
2001; 120: 1607–1619
65 Falk GW, Rice TW, Goldblum JR et al. Jumbo biopsy forceps protocol
still misses unsuspected cancer in Barrett’s esophagus with high-grade
dysplasia. Gastrointest Endosc 1999; 49: 170–176
66 Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and
proliferation in Barrett’s esophagus and the effects of acid suppression.
Gastroenterology 1999; 117: 327 –335
67 Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH
with high-dose proton pump inhibitor therapy does not result in regression
of Barrett’s esophagus. Am J Gastroenterol 1997; 92:
582–585
68 Wilkinson SP, Biddlestone L, Gore S et al. Regression of columnar-lined
(Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5
years of continuous therapy. Aliment Pharmacol Ther 1999; 13:
1205 –1209
69 Gore S, Healey CJ, Sutton R et al. Regression of columnar lined (Barrett’s)
oesophagus with continuous omeprazole therapy. Aliment
Pharmacol Ther 1993; 7: 623 – 628
70 Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole
treatment of patients with Barrett’s oesophagus. Aliment Pharmacol
Ther 1995; 9: 451–454
71 Peters FT, Ganesh S, Kuipers EJ et al. Endoscopic regression of Barrett’s
oesophagus during omeprazole treatment; a randomised double
blind study. Gut 1999; 45: 489 – 494
72 Cooper BT, Neumann CS, Cox MA et al. Continuous treatment with
omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus. Aliment
Pharmacol Ther 1998; 12: 893 – 897
73 Sagar PM, Ackroyd R, Hosie KB et al. Regression and progression of
Barrett’s oesophagus after antireflux surgery. Br J Surg 1995; 82:
806–810
74 McDonald ML, Trastek VF, Allen MS et al. Barrett’s esophagus: does an
antireflux procedure reduce the need for endoscopic surveillance?
J Thorac Cardiovasc Surg 1996; 111: 1135– 1138
75 Wang KK. Photodynamic therapy of Barrett’s esophagus. Gastrointest
Endosc Clin N Am 2000; 10: 409 – 419
76 Van Laethem JL, Cremer M, Peny MO et al. Eradication of Barrett’s mucosa
with argon plasma coagulation and acid suppression: immediate
and mid term results. Gut 1998; 43: 747 – 751
Leitlinie … Z Gastroenterol 2005; 43: 165 – 194 · DOI 10.1055/s-2005-857876
77 Pereira-Lima JC, Busnello JV, Saul C et al. High power setting argon
plasma coagulation for the eradication of Barrett’s esophagus. Am J
Gastroenterol 2000; 95: 1661–1668
78 Luman W, Lessels AM, Palmer KR. Failure of Nd-YAG photocoagulation
therapy as treatment for Barrett’s oesophagus – a pilot study. Eur J
Gastroenterol Hepatol 1996; 8: 627– 630
79 Wang KK, Sampliner RE. Mucosal ablation therapy of barrett esophagus.
Mayo Clin Proc 2001; 76: 433– 437
80 Gossner L, May A, Stolte M et al. KTP laser destruction of dysplasia and
early cancer in columnar-lined Barrett’s esophagus. Gastrointest Endosc
1999; 49: 8 – 12
81 Schulz H, Miehlke S, Antos D et al. Ablation of Barrett’s epithelium by
endoscopic argon plasma coagulation in combination with high-dose
omeprazole. Gastrointest Endosc 2000; 51: 659 – 663
82 Pelligrinin CA, Pohl D. High grade dyplasia in Barrett’s esophagus: surveillance
or operation? J Gastrointest Surg 2000; 4: 131 – 134
83 Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical
mortality in the United States. N Engl J Med 2002; 346:
1128 –1137
84 Barr H, Shepherd NA, Dix A et al. Eradication of high-grade dysplasia
in columnar-lined (Barrett’s) oesophagus by photodynamic therapy
with endogenously generated protoporphyrin IX. Lancet 1996; 348:
584 – 585
85 Gossner L, Stolte M, Sroka R et al. Photodynamic ablation of high-grade
dysplasia and early cancer in Barrett’s esophagus by means of
5-aminolevulinic acid. Gastroenterology 1998; 114: 448 – 455
86 Ackroyd R, Brown NJ, Davis MF et al. Photodynamic therapy for dysplastic
Barrett’s oesophagus: a prospective, double blind, randomised,
placebo controlled trial. Gut 2000; 47: 612 – 617
87 Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for
Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc
1999; 49: 1 – 7
88 Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for
Barrett’s esophagus with dysplasia and/or early stage carcinoma:
long-term results. Gastrointest Endosc 2003; 58: 183–188
89 Overholt BF, Lightdale C, Wang C et al. International, multicenter, partially
blinded randomised study of the efficacy of PDT using porfirmersodium
(POR) for the ablation of high-grade dysplasia (HGD) in
Barrett’s esophagus (BE): Results of 24-month follow-up. Gastroenterology
2003; 124 (Suppl): 151
90 Ell C, May A, Gossner L et al. Endoscopic mucosal resection of early
cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology
2000; 118: 670– 677
91 May A, Gossner L, Pech O et al. Local endoscopic therapy for intraepithelial
high-grade neoplasia and early adenocarcinoma in Barrett’s
oesophagus: acute-phase and intermediate results of a new treatment
approach. Eur J Gastroenterol Hepatol 2002; 1410: 1085
92 Van Laethem JL, Jagodzinski R, Peny MO et al. Argon plasma coagulation
in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma.
Endoscopy 2001; 33: 257 – 261
93 Pacifico RJ, Wang KK, Wongkeesong LM et al. Combined endoscopic
mucosal resection and photodynamic therapy versus esophagectomy
for management of early adenocarcinoma in Barrett’s esophagus. Clin
Gastroenterol Hepatol 2003; 1: 252 – 257
94 Stein HJ, Feith M, Mueller J et al. Limited resection for early adenocarcinoma
in Barrett’s esophagus. Ann Surg 2000; 232: 733–742
95 Banki F, Mason RJ, DeMeester SR et al. Vagal-sparing esophagectomy:
a more physiologic alternative. Ann Surg 2002; 236: 324–335
96 Ell C, May A, Gossner L et al. Kurative endoskopische Therapie früher
Adenokarzinome der Speiseröhre. Deutsches ¾rzteblatt 2003; 21:
A1438 –1448
97 Sibille A, Lambert R, Souquet JC et al. Long-term survival after photodynamic
therapy for esophageal cancer. Gastroenterology 1995; 108:
337–344